16 results
8-K
EX-99.1
YMAB
Y-Mabs Therapeutics Inc
9 Jan 24
Results of Operations and Financial Condition
6:45am
sites with licensed nuclear medicine radiologists High investment needed for specific infrastructure and manufacturing * Pending successful
8-K
EX-99.1
YMAB
Y-Mabs Therapeutics Inc
18 Oct 23
Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director
4:09pm
International. Michael earned a Bachelor of Science in Pharmacy from the University of the Sciences and holds an Authorized Nuclear Pharmacist
8-K
YMAB
Y-Mabs Therapeutics Inc
18 Oct 23
Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director
4:09pm
, Inc., a provider of detection, measurement, analysis and monitoring solutions to the nuclear defense, medical and research end markets, which he joined … in October 2022. Prior to that, Mr. Rossi was employed by Advanced Accelerator Applications, a Novartis subsidiary focused on nuclear medicine, from
8-K
jsbmcb
14 Jul 20
Y-mAbs Announces Update on SADA Technology and New Preclinical SADA Construct
9:06am
8-K
EX-99.1
0kgrjhxm ovfgzr
14 Jul 20
Y-mAbs Announces Update on SADA Technology and New Preclinical SADA Construct
9:06am
S-3
EX-4.7
2vcd4fa
1 Oct 19
Shelf registration
6:43pm
8-K
EX-10.1
iqucg 5a4k
19 Sep 19
Entry into a Material Definitive Agreement
4:50pm
DEF 14A
tgxfeedervrp242opl
30 Apr 19
Definitive proxy
3:50pm
8-K
EX-99.1
p99c2wj1
22 Mar 19
Y-mAbs Announces 2018 Financial Results and Corporate Development Highlights
4:02pm
8-K
EX-99.1
cydur6yu86wnlkr
11 Dec 18
Y-mAbs Announces Appointment of Gérard Ber to its Board of Directors and Planned Departure of Michael Buschle
4:42pm
- Prev
- 1
- Next